Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.
Drug: Recombinant Human Interleukin-2 and Rituximab
|Study Design:||Primary Purpose: Treatment|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00045877
Show 65 Study Locations